![VJHemOnc Podcast](https://pbcdn1.podbean.com/imglogo/image-logo/8189927/VJH_Thumbnail_1400b48w2.jpg)
58.4K
Downloads
272
Episodes
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
![Key updates on CAR-T & cellular therapy for AML](https://pbcdn1.podbean.com/imglogo/image-logo/8189927/VJH_Thumbnail_1400b48w2_300x300.jpg)
Tuesday May 18, 2021
Key updates on CAR-T & cellular therapy for AML
Tuesday May 18, 2021
Tuesday May 18, 2021
Acute myeloid leukemia (AML) is the most common type of leukemia in adults and is highly heterogenous. AML is typically treated with chemotherapy and allogeneic stem cell transplantation, however not all patients are eligible or able to tolerate these regimens, and many patients will experience relapse. Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated promising results in the treatment of B-cell lymphomas and is now being explored in AML, alongside other cellular therapies.
In this podcast, Saar Gill of the Perelman School of Medicines, PA, Richard Aplenc of the Children’s Hospital of Philadelphia, PA, Marion Subklewe of the LMU Hospital Munich in Germany, and Rizwan Romee of the Dana-Farber Cancer Institute, MA, discuss the latest data from clinical trials, comparing CAR-T therapy to other immunotherapeutic approaches, and outlining the potential role of CAR-NK cells in AML treatment.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.